The Numbers

We estimate the orthopedic market grew in the low single-digits as procedure volumes recovered across most categories.

Ortho Market Pressures Moderated in 3Q, Year-End Surge Unlikely

We estimate the orthopedic market grew in the low single-digits as procedure volumes recovered across most categories.

OrthAlign Lantern featuring Balance

Orthopedic Enabling Technology Startups Focused on Value

Orthopedic enabling technology startups are finding innovative ways to empower surgeons and improve healthcare economics.

This month’s chart examines the knee and hip replacement sales for the big four players from the beginning of 2019 through 3Q22.

Chart of the Month: Knee and Hip Recovery Trends

This month’s chart examines the knee and hip replacement sales for the big four players from the beginning of 2019 through 3Q22.

Medtronic Offsets VBP with Strength in U.S.

The company’s orthopedic sales grew in the mid-single-digits for FY 2Q23 on the strength of core spine and enabling technology in the U.S.

,
ZimVie Sees Substantial Opportunity in Enabling Technology

The company declined in the mid-teens for 3Q22 as it works through its transformation but sees unmet needs that enabling tech could address.

,
Bioventus Lowers 2022 Guidance, Pauses M&A

The company’s 3Q22 orthopedic revenue grew more than 20% but changes to viscosupplement reimbursement will be a headwind through 1H23.

,
Chart of the Month: Knee and Hip Recovery Trends

This month’s chart examines the knee and hip replacement sales for the big four players from the beginning of 2019 through 3Q22.

,
Ortho Market Pressures Moderated in 3Q, Year-End Surge Unlikely

We estimate the orthopedic market grew in the low single-digits as procedure volumes recovered across most categories.

,
Medtronic Offsets VBP with Strength in U.S.

The company’s orthopedic sales grew in the mid-single-digits for FY 2Q23 on the strength of core spine and enabling technology in the U.S.

,
ZimVie Sees Substantial Opportunity in Enabling Technology

The company declined in the mid-teens for 3Q22 as it works through its transformation but sees unmet needs that enabling tech could address.

,
Bioventus Lowers 2022 Guidance, Pauses M&A

The company’s 3Q22 orthopedic revenue grew more than 20% but changes to viscosupplement reimbursement will be a headwind through 1H23.

,
Chart of the Month: Knee and Hip Recovery Trends

This month’s chart examines the knee and hip replacement sales for the big four players from the beginning of 2019 through 3Q22.

,
Ortho Market Pressures Moderated in 3Q, Year-End Surge Unlikely

We estimate the orthopedic market grew in the low single-digits as procedure volumes recovered across most categories.

,
Anika Remains On Track For 2022 Guidance

The company grew below 1% in 3Q22 due to a difficult prior year comparison, supply chain headwinds and slowly recovering elective procedures.

,
SI-BONE Set for Reimbursement Tailwinds

The company grew more than 18% in 3Q22 and will benefit from substantial CMS fee increases in ASCs for 2023.

,
NuVasive Focused on Long Term Growth Strategy

The company grew in high single-digits for 3Q22 on the strength of case volume recovery and its portfolio of procedural solutions.

,
Treace Benefits from Commercial Investments

The company grew by more than 52% in 3Q22, spurred by accelerating contributions from its direct sale force.

,
Paragon 28 Growth Driven by New Product Cadence

The company grew over 28% in 3Q22, as new product introductions attract new surgeons and drive sales force expansions.

,

Contact Us

0